Treatment combinations targeting apoptosis to improve immunotherapy of melanomaHERSEY, Peter; XU DONG ZHANG.Cancer immunology and immunotherapy. 2009, Vol 58, Num 11, pp 1749-1759, issn 0340-7004, 11 p.Article

Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanomaGRAY, Christian P; AROSIO, Paolo; HERSEY, Peter et al.Clinical cancer research. 2003, Vol 9, Num 7, pp 2551-2559, issn 1078-0432, 9 p.Article

Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cellsGRAY, Christian P; AROSIO, Paolo; HERSEY, Peter et al.Blood. 2002, Vol 99, Num 9, pp 3326-3334, issn 0006-4971Article

Docetaxel-lnduced apoptosis of human melanoma is mediated by activation of c-jun NH₂-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathwayMHAIDAT, Nizar M; XU DONG ZHANG; CHEN CHENJIANG et al.Clinical cancer research. 2007, Vol 13, Num 4, pp 1308-1314, issn 1078-0432, 7 p.Article

Immunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 productionGRAY, Christian P; FRANCO, Agustin V; AROSIO, P et al.International journal of cancer. 2001, Vol 92, Num 6, pp 843-850, issn 0020-7136Article

New Challenges in Endpoints for Drug Development in Advanced MelanomaRIBAS, Antoni; HERSEY, Peter; MIDDLETON, Mark R et al.Clinical cancer research (Print). 2012, Vol 18, Num 2, pp 336-341, issn 1078-0432, 6 p.Article

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed MelanomaKIRKWOOD, John M; LORIGAN, Paul; HERSEY, Peter et al.Clinical cancer research (Print). 2010, Vol 16, Num 3, pp 1042-1048, issn 1078-0432, 7 p.Article

Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cellsCHEN CHEN JIANG; ZHI GANG MAO; AVERY-KIEJDA, Kelly A et al.Carcinogenesis (New York. Print). 2009, Vol 30, Num 2, pp 197-204, issn 0143-3334, 8 p.Article

Inhibition of Endoplasmic Reticulum Stress-Induced Apoptosis of Melanoma Cells by the ARC ProteinLI HUA CHEN; CHEN CHEN JIANG; WATTS, Ralph et al.Cancer research (Baltimore). 2008, Vol 68, Num 3, pp 834-842, issn 0008-5472, 9 p.Article

Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanomaHERSEY, Peter; MENZIES, Scott W; COVENTRY, Brendon et al.Cancer immunology and immunotherapy. 2005, Vol 54, Num 3, pp 208-218, issn 0340-7004, 11 p.Article

Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanomaBRON, Luc P; SCOLYER, Richard A; THOMPSON, John F et al.Pathology (Sydney). 2004, Vol 36, Num 6, pp 561-565, issn 0031-3025, 5 p.Article

Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondriaXU DONG ZHANG; BORROW, Jodie M; XI YI ZHANG et al.Oncogene (Basingstoke). 2003, Vol 22, Num 19, pp 2869-2881, issn 0950-9232, 13 p.Article

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic MelanomaTRUNZER, Kerstin; PAVLICK, Anna C; HERSEY, Peter et al.Journal of clinical oncology. 2013, Vol 31, Num 14, pp 1767-1774, issn 0732-183X, 8 p.Article

A Randomized Phase 2 Study of Etaracizumab, a Monoclonal Antibody Against Integrin α_vβ₃, ± Dacarbazine in Patients With Stage IV Metastatic MelanomaHERSEY, Peter; SOSMAN, Jeffrey; HAMMERSHAIMB, Luz et al.Cancer. 2010, Vol 116, Num 6, pp 1526-1534, issn 0008-543X, 9 p.Article

Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor - related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatinXU DONG ZHANG; JING JING WU; GILLESPIE, Susan et al.Clinical cancer research. 2006, Vol 12, Num 4, pp 1355-1364, issn 1078-0432, 10 p.Article

Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligandLIQING ZHUANG; SOON LEE, C; SCOLYER, Richard A et al.Human pathology. 2006, Vol 37, Num 10, pp 1286-1294, issn 0046-8177, 9 p.Article

MEK-Independent Survival of B-RAF^V600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720CHEN CHEN JIANG; LAI, Fritz; THORNE, Rick F et al.Clinical cancer research (Print). 2011, Vol 17, Num 4, pp 721-730, issn 1078-0432, 10 p.Article

Results of a Multicenter, Randomized, Double-Blind Phase 2/3 Study of Lenalidomide in the Treatment of Pretreated Relapsed or Refractory Metastatic Malignant MelanomaEISEN, Tim; TREFZER, Uwe; HAMILTON, Anne et al.Cancer. 2010, Vol 116, Num 1, pp 146-154, issn 0008-543X, 9 p.Article

Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanomaRANSON, Malcolm; HERSEY, Peter; BAKA, Sofia et al.Journal of clinical oncology. 2007, Vol 25, Num 18, pp 2540-2545, issn 0732-183X, 6 p.Article

Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosisCHEN CHEN JIANG; LI HUA CHEN; GILLESPIE, Susan et al.Cancer research (Baltimore). 2007, Vol 67, Num 20, pp 9750-9761, issn 0008-5472, 12 p.Article

Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein responseLI HUA CHEN; CHEN CHEN JIANG; KIEJDA, Kelly A et al.Carcinogenesis (New York. Print). 2007, Vol 28, Num 11, pp 2328-2336, issn 0143-3334, 9 p.Article

Microarray expression profiling in melanoma reveals a BRAF mutation signaturePAVEY, Sandra; JOHANSSON, Peter; HANSEN, Katherine et al.Oncogene (Basingstoke). 2004, Vol 23, Num 23, pp 4060-4067, issn 0950-9232, 8 p.Article

Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1SALEH, Farid H; CROTTY, Kerry A; HERSEY, Peter et al.International journal of cancer. 2001, Vol 94, Num 4, pp 551-557, issn 0020-7136Article

Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosisTAM NGUYEN; XU DONG ZHANG; HERSEY, Peter et al.Clinical cancer research. 2001, Vol 7, Num 3, pp 966s-973s, issn 1078-0432, SUPConference Paper

Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in MelanomaHAMID, Omid; ROBERT, Caroline; DRONCA, Roxana et al.The New England journal of medicine. 2013, Vol 369, Num 2, pp 134-144, issn 0028-4793, 11 p.Article